---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-048553"
form_type: "8-K"
ticker: "LABT"
cik: "0002079272"
company_name: "Lakewood-Amedex Biotherapeutics Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:17:34.379824+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Appoints Joseph Tucker to board; $6,000/quarter stock + 33,784 warrants at $10

## Summary
- Dr. Joseph Tucker appointed to Board, effective April 24, 2026, until 2027 annual meeting.
- Compensation: $6,000 per quarter in common stock; granted 33,784 warrants at $10.00, 10-year term.
- Warrants vest in 4 equal tranches: Oct 24, 2026; Apr 24, 2027; Oct 24, 2027; Apr 24, 2028.
- Tucker is CEO of Enveric Biosciences (NASDAQ: ENVB) with over $100M capital raised track record.
- Appointment follows LABT's recent Nasdaq direct listing; Tucker joins Audit, Compensation, Governance committees.

## SEC filing metadata
- accession: 0001213900-26-048553
- form_type: 8-K
- ticker: LABT
- cik: 0002079272
- company_name: Lakewood-Amedex Biotherapeutics Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026048553/0001213900-26-048553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2079272/000121390026048553/ea0287960-8k_lakewood.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-048553
- JSON: https://secwatch.observer/filing/0001213900-26-048553.json
- Plain text: https://secwatch.observer/filing/0001213900-26-048553.txt

## Key facts
- Executive change
  Joseph Tucker was appointed as Director at Lakewood-Amedex Biotherapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2079272/000121390026048553/0001213900-26-048553-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.